LDL ApoB and Cumulative Exposure

The causal model behind the lipid axis. Most of the wiki’s cardiovascular reasoning runs on LDL-C (cholesterol mass). The EAS Consensus (Ference et al. 2017) supplies the causal framework underneath it — and it reframes three things: what causes the disease (apoB particles, not cholesterol mass per se), how the dose works (cumulative exposure, not current level), and which number to trust (apoB over LDL-C in the metabolically-impaired).

LDL/apoB CAUSES ASCVD — a causality verdict, not an association

The consensus assessed the LDL-ASCVD link against Bradford Hill-style causality criteria across four independent method families — genetic studies, prospective cohorts, Mendelian randomization, and LDL-lowering RCTs — and reached an unusually strong verdict:

«Consistent evidence from numerous and multiple different types of clinical and genetic studies unequivocally establishes that LDL causes ASCVD.» [EXTRACTED (Ference - LDL Cause ASCVD EAS Consensus 2017) chunk 01]

The causal agent is not LDL-cholesterol as such but the apoB-containing particles that carry it:

«cholesterol-rich LDL and other apolipoprotein B (apoB)-containing lipoproteins, including very low-density lipoproteins (VLDL) and their remnants, intermediate density lipoproteins (IDL), and lipoprotein(a) [Lp(a)], are directly implicated in the development of ASCVD.» [EXTRACTED (Ference - LDL Cause ASCVD EAS Consensus 2017) chunk 01]

This is the strongest form of the surrogate-vs-outcome question resolved in the validated direction: LDL/apoB is the exemplar of a surrogate whose causal transmission to the hard outcome is itself evidenced — the opposite of the marker moved, patient did worse cases -> Surrogate Outcomes. The verdict rests on the concordance between the naturally-randomized genetic/MR evidence (unconfounded, lifelong exposure) and the LDL-lowering RCTs (intervene on LDL, the outcome moves — the source’s most compelling causal evidence): the natural experiment and the intervention agreeing, the top of the mechanism-strength gradient, not a mechanistic story.

The dose is CUMULATIVE — magnitude x duration, not current level

The dose-response is log-linear across >2 million participants and >150,000 events, and it compounds with time:

«any mechanism of lowering plasma LDL particle concentration should reduce the risk of ASCVD events proportional to the absolute reduction in LDL-C and the cumulative duration of exposure to lower LDL-C, provided that the achieved reduction in LDL-C is concordant with the reduction in LDL particle number and that there are no competing deleterious off-target effects.» [EXTRACTED (Ference - LDL Cause ASCVD EAS Consensus 2017) chunk 01]

Two decision consequences follow:

• Lower for longer beats lower later. Because risk tracks the area under the LDL/apoB curve over a lifetime, a modest reduction sustained for decades can outweigh a larger one started late — the cumulative-exposure frame, which a single current LDL-C snapshot cannot capture.
• Mechanism-agnostic, if concordant. Any route that lowers apoB particle concentration (diet, statins, PCSK9 inhibitors) reduces risk in proportion to the reduction achieved — provided the LDL-C drop reflects a real particle-number drop and carries no off-target harm. This is what licenses reading a diet’s LDL effect (Saturated Fat Intake and Replacement) and a drug’s LDL effect (Statins for Primary Prevention and the Power of Zero CAC) on the same causal scale.

Measure apoB, not just LDL-C, in the metabolically-impaired — they DISCORD

The concordance proviso above is not academic — it breaks exactly where the wiki’s drifting-median stratum sits:

«in certain conditions (e.g. the metabolic syndrome, diabetes, and hypertriglyceridaemia), plasma LDL-C and LDL particle concentration can become discordant as a result of the predominance of small, dense cholesterol-poor LDL, and therefore plasma LDL-C may not accurately reflect LDL particle concentration or its effect on cardiovascular risk. Under these conditions, direct measurement of LDL particle number or apoB concentration (recognizing that each LDL particle contains a single apoB molecule) may more accurately reflect the causal effect of LDL on ASCVD.» [EXTRACTED (Ference - LDL Cause ASCVD EAS Consensus 2017) chunk 01]

So for an insulin-resistant, hypertriglyceridemic adult, LDL-C can under-state the atherogenic particle burden — the small-dense-LDL pattern packs more particles (more apoB) into a given cholesterol mass. This is the resolution of the carnivore critique’s open question (Axis 1 reasoned on LDL-C; the causal quantity is apoB, and in this stratum they diverge — apoB is the number to trust).

LDL-P vs apoB vs LDL-C (Challenge #18). Three ways to count the same causal thing, and the ranking is apoB >= LDL-P > LDL-C for reflecting the atherogenic-particle burden:

• LDL-C is a good particle surrogate MOST of the time — «Under most conditions, LDL-C concentration and LDL particle number are highly correlated, and therefore plasma LDL-C is a good surrogate»; it only fails in the discordant (metabolic-syndrome / diabetic / hypertriglyceridemic) state. So LDL-P/apoB add little for the concordant, lean person and a lot for this stratum.
• LDL-P (particle number, by NMR) approximates apoB far better than LDL-C does — both are counts, and «each LDL particle contains a single apoB molecule», so LDL-P ≈ apoB for the LDL fraction.
• But apoB is the more COMPLETE measure, and that gap widens exactly where it matters. apoB counts all apoB-containing particles — LDL plus VLDL and their remnants, IDL, and Lp(a) — whereas LDL-P counts only LDL. Those remnant/IDL particles are elevated precisely in the hypertriglyceridemic / metabolic-syndrome state, so LDL-P misses the extra atherogenic particles apoB captures right where discordance arises. apoB is also the more standardised, widely-available assay. So LDL-P is a good LDL-only proxy for apoB; apoB is the target. `[EXTRACTED for the correlation + single-apoB-per-particle
  • the particle list; INFERRED for the remnant-coverage ranking, which follows from apoB’s particle set vs LDL-P’s]`

Limits

• Single-source (one consensus statement), confidence: medium. The evidence Ference synthesizes is strong (genetic/MR/RCT triangulation), but the wiki holds one source for the framework; a second independent statement or the primary MR/RCT evidence would raise it.
• Causal ≠ the only lever. LDL/apoB causation does not make it the largest absolute lever for a given person — absolute benefit still scales with baseline risk (Baseline Risk and the Relative-Absolute Split), and the net of a diet or drug depends on the whole strategy, not the LDL number alone.
• Off-target caveat is load-bearing: the any-mechanism-works claim is conditioned on no competing deleterious off-target effects — a real diet or drug can lower LDL and still net-harm through another pathway, so this validates the lipid channel, not any intervention wholesale.

A contested refinement — is a DIET-induced LDL-C change a good apoB proxy? (Astrup et al. 2020) [2026-07-29]

Astrup - Saturated Fats Reassessment 2020 presses the concordance proviso above in a specific direction: it argues a diet-induced LDL-C reduction from SFA restriction is an unusually poor proxy for the atherogenic-particle change, so CVD benefit inferred from it is overstated. The claim, and where it stands against this page:

• It CONCEDES the causal core — “LDL particles play a causal role in the development of CVD” and there is “a relationship between lowering of LDL cholesterol and CVD benefit.” So this is not LDL-denial; it is a claim about the diet-induced change specifically. [EXTRACTED (Astrup - Saturated Fats Reassessment 2020) chunk 01, LDL Cholesterol and Other Biomarkers]
• The argument: SFA restriction lowers mainly “large LDL particle subspecies… which are much less strongly related to CVD risk,” not the small dense LDL, and also lowers HDL — so the total:HDL ratio barely moves and “the potential benefit of dietary restriction of saturated fat could be substantially overestimated by reliance on the change in LDL cholesterol levels alone.”
• PURE grounds the diet-lipid discordance with data (now a held source). Dehghan - PURE Fats Carbohydrate Mortality 2017 (via its companion Mente 2017 lipid analysis) reports higher SFA → higher LDL but higher HDL, lower triglycerides, and lower ApoB/ApoA1 ratio (the stronger predictor), while higher carbohydrate → lower LDL but higher ApoB/ApoA1 — concluding «predicting the net clinical effect based on considering only the effects of nutrient intake on LDL cholesterol is not reliable». [EXTRACTED (Dehghan - PURE Fats Carbohydrate Mortality 2017) chunk 01, Discussion] This is the discordance-in-the-diet-direction claim in cohort data — and note it is itself an apoB argument (the hazard tracked apoB/apoA1, not LDL-C), so it reinforces measure apoB, this page’s held view, rather than displacing it. Observational and confounded by income, so directional not decisive.
• Where it lands against this page’s model. This page already holds the discordance mechanism — in the metabolic-syndrome/diabetic/hypertriglyceridemic state, LDL-C under-states apoB particle number, so measure apoB. Astrup and Ference agree LDL-C is an imperfect proxy and apoB is the target; they diverge on direction for the SFA case (Astrup: SFA raises mostly the benign large fraction, so diet-LDL overstates harm). The large-vs-small-LDL distinction Astrup leans on is substantially superseded by apoB particle number as the summary causal quantity (this page’s held view) — apoB counts the particles regardless of size, and PURE’s apoB/apoA1 signal is itself an apoB argument. So the honest status: the diet-induced-LDL-C caveat is real and this page already carries its mechanism (measure apoB, not LDL-C); the further claim that SFA’s LDL rise is benign-by-particle-size is contested and dated, and does not overturn apoB causality. [INFERRED (Astrup - Saturated Fats Reassessment 2020; Ference - LDL Cause ASCVD EAS Consensus 2017) — the reconciliation (agree on apoB target, diverge on the SFA direction; particle-size superseded by apoB number) is this page's; each source's own claim is quoted/attributed] -> full joined issue: Does Reducing Saturated Fat Reduce Cardiovascular Events.

Self-critique [run 2026-07-29, before commit]

• Over-claim check: the causal verdict is quoted from the consensus, not asserted by the wiki; the lower for longer and measure apoB consequences are tagged to the source’s own proviso (concordance
  • no off-target). The single-source/confidence: medium limit is stated.
• Surrogate framing: LDL/apoB is presented as the validated-surrogate exemplar, explicitly the counter-case to the wiki’s usual surrogate caution — not a licence to trust surrogates generally.
• Mechanism-gradient discipline (cold-audit fix): the causal weight is attributed to the concordance of the genetic/MR evidence AND the LDL-lowering RCTs (the source’s own pillar; the RCTs are its most compelling causal evidence), not to genetic/MR alone — the top of the mechanism-strength gradient, not a mechanistic plausibility story.